Nishkarsh Jain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nishkarsh Jain has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Jayanth Kumar Palanichamy
Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
1 shared publication - Kalpana Luthra
Department of Biochemistry, All India Institute of Medical Sciences
1 shared publication - Nitesh Mishra
Scripps Research Institute, San Diego, USA
1 shared publication Rajesh Kumar
Affiliation Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India
1 shared publicationRiyaz Ahmad Mir
Affiliation Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
1 shared publication- Sanjeev Kumar
Division of Infectious Disease, Department of Pediatrics, Center for Childhood Infections and Vaccines (CCIV), Emory University School of Medicine
1 shared publication
Latest Publications
- Open Access
- 24 September 2021
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (9) , e1009958
Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma
Cross-reactive epitopes (CREs) are similar epitopes on viruses that are recognized or neutralized by same antibodies. The S protein of SARS-CoV-2, similar to type I fusion proteins of viruses such as HIV-1 envelope (Env) and influenza hemagglutinin, is heavily glycosylated. Viral Env glycans, though host derived, are distinctly processed and thereby recognized or accommodated during antibody responses. In recent years, highly potent and/or broadly neutralizing human monoclonal antibodies (bnAbs) that are generated in chronic HIV-1 infections have been defined. These bnAbs exhibit atypical features such as extensive somatic hypermutations, long complementary determining region (CDR) lengths, tyrosine sulfation and presence of insertions/deletions, enabling them to effectively neutralize diverse HIV-1 viruses despite extensive variations within the core epitopes they recognize. As some of the HIV-1 bnAbs have evolved to recognize the dense viral glycans and cross-reactive epitopes (CREs), we assessed if these bnAbs cross-react with SARS-CoV-2. Several HIV-1 bnAbs showed cross-reactivity with SARS-CoV-2 while one HIV-1 CD4 binding site bnAb, N6, neutralized SARS-CoV-2. Furthermore, neutralizing plasma antibodies of chronically HIV-1 infected children showed cross neutralizing activity against SARS-CoV-2 pseudoviruses. Collectively, our observations suggest that human monoclonal antibodies tolerating extensive epitope variability can be leveraged to neutralize pathogens with related antigenic profile.
- 24 September 2021
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 17 (9) , e1009958
Open AccessCross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma
Cross-reactive epitopes (CREs) are similar epitopes on viruses that are recognized or neutralized by same antibodies. The S protein of SARS-CoV-2, similar to type I fusion proteins of viruses such as HIV-1 envelope (Env) and influenza hemagglutinin, is heavily glycosylated. Viral Env glycans, though host derived, are distinctly processed and thereby recognized or accommodated during antibody responses. In recent years, highly potent and/or broadly neutralizing human monoclonal antibodies (bnAbs) that are generated in chronic HIV-1 infections have been defined. These bnAbs exhibit atypical features such as extensive somatic hypermutations, long complementary determining region (CDR) lengths, tyrosine sulfation and presence of insertions/deletions, enabling them to effectively neutralize diverse HIV-1 viruses despite extensive variations within the core epitopes they recognize. As some of the HIV-1 bnAbs have evolved to recognize the dense viral glycans and cross-reactive epitopes (CREs), we assessed if these bnAbs cross-react with SARS-CoV-2. Several HIV-1 bnAbs showed cross-reactivity with SARS-CoV-2 while one HIV-1 CD4 binding site bnAb, N6, neutralized SARS-CoV-2. Furthermore, neutralizing plasma antibodies of chronically HIV-1 infected children showed cross neutralizing activity against SARS-CoV-2 pseudoviruses. Collectively, our observations suggest that human monoclonal antibodies tolerating extensive epitope variability can be leveraged to neutralize pathogens with related antigenic profile.